Supernus announces expiration of HSR waiting period for Sage Therapeutics

Supernus Pharmaceuticals (SUPN) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (SAGE), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger, by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus. On June 25, 2025 and June 30, 2025, Supernus and Sage, respectively, filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the Offer. The Offer continues to be subject to the remaining conditions set forth in the Offer to Purchase, dated July 2, 2025 and in the related Letter of Transmittal. The Offer and withdrawal rights will expire at one minute following 11:59 p.m., Eastern Time, on July 30, 2025, unless the Offer is extended or earlier terminated.